Synopses & Reviews
The economic burden of dementia was estimated as being US$ 604 billion in 2010. Now it is time for new guidelines in handling of neurodegenerative disorders. Optimistic versus Pessimistic Prognosis depends much on diagnostic and treatment approaches which healthcare will preferably adopt in the near future. Current dramatic situation can be significantly improved by the implementation of appropriate early diagnostic, targeted preventive measures and therapies tailored to the person advancing healthcare and enhancing the patient life quality. Neurodegenerative Diseases are pathologies of multi-factorial nature involving interplay of epi/genetic and environmental risk factors. Insights into molecular pathomechanisms will enable to create the most effective neuro-protective strategies and individualised treatment before manifest pathology. Utilization of the advanced integrative medical approach could enable a significant portion of population to reach the 100-year age limit remaining vibrant in excellent physical and mental health as actively contributing members of the society. The crucial role of the integrative approach by PPPM has been acknowledged as priorities by World Health Organization, United Nations and the European Union among others. Extensive efforts of international consortia are essential in the field to consolidate the accumulated expertise and to create population screening, robust diagnostic approaches, effective prevention in groups at high risk and targeted treatments. This book volume "Neurodegenerative Diseases: Integrative PPPM Approach as the Medicine of the Future" is intended to serve as a reference source for basic researchers and healthcare industry involved in the field of neurosciences with a special emphasis on mental health promotion and innovations intended to delay or even prevent neurodegenerative diseases.
This book will compile a collection of chapters dedicated to varied aspects of PPPM in neuropsychiatric and neurodegenerative diseases. Among the topics to be covered are: Recent advances in ALS research News about Clinical aspects and advanced therapy approaches in personalized treatment of ALS Schizophrenia: New treatments and clinical aspects Predictive, Preventive and Personalised Medicine in aging macular degeneration Advances in Multiple Sclerosis Pharmacogenetics, Tailoring Treatment Efficacy, Safety and Regimen Selection Multiple sclerosis related biomarkers: perspectives for clinical application Preventive clinical trials in brain aging: new trends & the need of guidelines MCI_ clinical guidelines in early diagnosis of dementia Alzheimer's disease: diagnostics, prognostics and the road to prevention Biomarkers for early diagnosis of Parkinson's and Alzheimer's diseases Synucleinopathies, tauopathies, TDP-43 proteinopathies and amyloidosis PSP, MSA and other parkinsonisms
Table of Contents
Part I 1. What is this book series about? Foreword of Book Series Editor; O. Golubnitschaja 2. Preface; S. Mandel 3.